1. Current and Future Goals in the Treatment of Relapsed CLL

3. This program will include a discussion of data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

4. Program Goals

5. Using Ibrutinib After Chemoimmunotherapy

6. Rechallenging With Chemoimmunotherapy: Risk for AML/MDS

7. Rechallenging With Chemoimmunotherapy: Salvage BR

8. Combination Regimens With Chemoimmunotherapy and Novel Agents

9. Using Idelalisib-Based Therapy After Chemoimmunotherapy

10. Defining Relapse/Disease Progression: Considerations With Novel Agents

11. Assessing Lymphocytosis in Patients Treated With Ibrutinib

12. Therapy Selection After Ibrutinib

13. Effect of Dose Adherence on Outcomes With Ibrutinib

14. Selecting a BCR Signaling Inhibitor: Clinical Considerations

15. AF in Patients Treated With Ibrutinib Therapy

16. Immune-Mediated Effects in Patients Treated With Idelalisib-Based Therapy

17. Considerations in Treatment Selection After Ibrutinib Discontinuation: Toxicity

18. Considerations in Treatment Selection After Ibrutinib Discontinuation: Disease Progression

19. Using Del(17p) and TP53 Mutation Status in Treatment Selection

20. Influence of Complex Karyotype on Treatment Selection

21. Managing Patients With Richter Transformation

22. MRD Negativity as a Treatment Goal

23. Allogeneic SCT in Relapsed CLL: Clinical Considerations

24. Treatment Options After BCR Signaling Inhibitors and Bcl2 Inhibitor

25. CAR T-Cell Therapy After Ibrutinib Therapy

26. Managing Patients With Relapsed CLL: Future Approaches

27. Conclusions

28. Abbreviations

29. Abbreviations (cont)

30. Abbreviations (cont)